Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Nanotechnology Helps Track and Improve Drug Action in Pancreatic Cancer

Published: Wednesday, June 26, 2013
Last Updated: Wednesday, June 26, 2013
Bookmark and Share
Scientists have been able to show ways in which we can markedly improve drug targeting of solid tumours, using ‘biosensors’ along with imaging techniques.

In real time and in three dimensions, these technologies can show us how cancers spread and how active cancer cells respond to a particular drug. They can also tell us how much, how often and how long to administer drugs. Finally, using preclinical models of the disease, they can guide the use of ‘combination therapies’, techniques that enhance drug delivery by breaking up the tissue surrounding a tumour.

The study was performed by Dr Paul Timpson of the Garvan Institute of Medical Research and Professor Kurt Anderson of the Beatson Institute for Cancer Research in Glasgow, UK.  PhD student Max Nobis studied the signaling protein ‘Src’, which becomes activated to drive invasive pancreatic cancer, and looked at how it could best be deactivated by a small molecule inhibitor — currently in phase II clinical trials — known as ‘dasatinib’. Their findings are published in the journal Cancer Research, now online.

“We have already shown that Src is activated in pancreatic tumours and we knew that dasatinib deactivates Src and could partially reduce the spread of this form of cancer. Through a collaborative partner in the US, we had access to FRET (Fluorescence Resonance Energy Transfer) imaging technology,” said Dr Paul Timpson.

“Until now, we have been limited to studying tumour signalling in two dimensions – and lacked a dynamic way of reporting on drug targeting in live tumour tissue.  Nanotechnology opens up a portal into living tissue that allows us to watch cancers spreading, and to determine which parts of a tumour we should be targeting with drugs.”

“This imaging technology has allowed us to map areas within the tumour that are highly aggressive, allowing us to pinpoint regions of poor drug delivery deep within a tumour at sub-cellular resolution. We can then see where we need to improve on drug delivery to improve clinical outcome.”

It has been hard to treat pancreatic tumours because they are extremely dense with collagen and have poor blood vessel networks for delivering drugs.

Professor Kurt Anderson observed that combination therapies can now be used to break down collagen, weakening tumour architecture and making it easier to get the drugs where they need to be. “The trick is to break down the structure just enough to get the drug in, but not so much that you damage the organ itself,” he said.

“These new FRET technologies help us gauge what is just enough and not too much.”

“These are very exciting discoveries – we now have spatial and temporal information about cancer behaviour that we’ve never had before, as well as the nanotechnology to monitor and improve drug delivery in hard to reach tumour regions.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

The Switch That Might Tame The Most Aggressive Of Breast Cancers
Garvan researchers have found that so-called ‘triple-negative breast cancers’ are two distinct diseases that likely originate from different cell types. They have also found a gene that drives the aggressive disease, and hope to find a way to ‘switch it off’.
Monday, March 30, 2015
Epigenetic Signatures that Differentiate Triple-Negative Breast Cancers
Australian researchers have identified epigenetic ‘signatures’ that could help clinicians tell the difference between highly aggressive and more benign forms of triple-negative breast cancer.
Tuesday, February 03, 2015
The Genome’s 3D Structure Shapes how Genes are Expressed
Scientists bring new insights to our understanding of the three-dimensional structure of the genome.
Wednesday, June 26, 2013
Scientific News
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Farming’s in Their DNA
Ancient genomes reveal natural selection in action.
GMO Food Animals Should be Judged by Product, Not Process
In a world with a burgeoning demand for meat, milk and eggs, regulatory policies around the use of biotechnologies in agriculture need to be based on the safety and attributes of those foods rather than on the methods used to produce them, says a UC Davis animal scientist.
Enzyme Critical to Maintaining Telomere Length Discovered
New method expected to speed understanding of short telomere diseases and cancer.
Gene Drive Reversibility Introduces New Layer of Biosafety
Ability to introduce or reverse the spread of genetic traits through populations could one day improve pest management and disease control.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos